Top

Published in:

01-12-2020 | Tocilizumab | Letter to the Editors

Mild COVID-19 infection in an NMO patient treated with tocilizumab: a confirmation of anti-IL-6 protective role?

Authors: Vittorio Mantero, Andrea Rigamonti, Paola Basilico, Marta Crespi, Roberto Balgera, Andrea Salmaggi

Excerpt

Dear Editor, …

Chen G, Wu D, Guo W et al (2020) Clinical and immunologic features in severe and moderate coronavirus disease 2019. J Clin Invest 130:2620–2629. https://doi.org/10.1172/JCI137244CrossRefPubMedPubMedCentral

Emmi G, Bettiol A, Mattioli I et al (2020) SARS-CoV-2 infection among patients with systemic autimmune diseases. Autoimmun Rev 19:102575. https://doi.org/10.1016/j.autrev.2020.102575CrossRefPubMedPubMedCentral

Mehta P, McAuley DF, Brown M et al (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395:1033–1034. https://doi.org/10.1016/S0140-6736(20)30628-0CrossRefPubMedPubMedCentral

Creed MA, Ballesteros E Jr, Imitola J (2020) Mild COVID-19 infection despite chronic B cell depletion in a patient with aquaporin-4-positive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 44:102199. https://doi.org/10.1016/j.msard.2020.102199CrossRefPubMedPubMedCentral

Zhang C, Zhang M, Qiu W et al (2020) Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol 19:391–401. https://doi.org/10.1016/S1474-4422(20)30070-3CrossRefPubMedPubMedCentral

Carnero Contentti E, Correa J (2020) Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: a new challenge. Mult Scler Relat Disord 41:102097. https://doi.org/10.1016/j.msard.2020.102097CrossRefPubMedPubMedCentral

Brownlee W, Bourdette D, Broadley S, Killestein J, Ciccarelli O (2020) Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic. Neurology 94:949–952. https://doi.org/10.1212/WNL.0000000000009507CrossRefPubMed

Zhang S, Li L, Shen A, Chen Y, Qi Z (2020) Rational use of tocilizumab in the treatment of novel coronavirus pneumonia. Clinical Drug Investig 40:511–518. https://doi.org/10.1007/s40261-020-00917-3CrossRef

Xu X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X, Zhang X, Pan A, Wei H (2020) Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA 117(20):10970–10975. https://doi.org/10.1073/pnas.2005615117CrossRefPubMedPubMedCentral

10.

Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J (2020) Tocilizumab treatment in COVID-19: a single center experience. J Med Virol 92:814–818. https://doi.org/10.1002/jmv.25801CrossRefPubMed

11.

Alattar R, Ibrahim TBH, Shaar SH, Abdalla S, Shukri K, Daghfal JN et al (2020) Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol. https://doi.org/10.1002/jmv.25964CrossRefPubMedPubMedCentral

12.

Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F et al (2020) Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev 19:102568. https://doi.org/10.1016/j.autrev.2020.102568CrossRefPubMedPubMedCentral

13.

Sormani MP (2020) An Italian programme for COVID-19 infection in multiple sclerosis. Lancet Neurol. https://doi.org/10.1016/S1474-4422(20)30147-2CrossRefPubMedPubMedCentral

14.

Novi G, Mikulska M, Briano F et al (2020) COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? Mult Scler Relat Disord 42:102120. https://doi.org/10.1016/j.msard.2020.102120CrossRefPubMedPubMedCentral

15.

Safavi F, Nourbakhsh B, Azimi AR (2020) B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord 43:102195. https://doi.org/10.1016/j.msard.2020.102195CrossRefPubMedPubMedCentral

Title: Mild COVID-19 infection in an NMO patient treated with tocilizumab: a confirmation of anti-IL-6 protective role?
Authors: Vittorio Mantero
Andrea Rigamonti
Paola Basilico
Marta Crespi
Roberto Balgera
Andrea Salmaggi
Publication date: 01-12-2020
Publisher: Springer Berlin Heidelberg
Keywords: Tocilizumab
SARS-CoV-2
Neuromyelitis Optica Spectrum Disease
COVID-19
Cytokines
Published in: Journal of Neurology / Issue 12/2020
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-020-10039-7